In the letter, Mr. Riis discussed the company’s position on drug affordability and listed three main initiatives the company will take that revolve around creating more pricing predictability, transforming the drug pricing system and reducing the burden of out-of-pocket costs to patients.
“We hear from more and more people living with diabetes about the challenges they face affording healthcare, including the medicines we make. We take this issue seriously and have been thinking about what we can do to better support patients,” Mr. Riss wrote in the letter. “This has become a responsibility that needs to be shared among all those involved in healthcare and we’re going to do our part.”
Mr. Riis’ initiative follows the stance Allergan CEO Brent Saunders took against high drug prices in September when he promised to limit price increases through a social contract with consumers.
More articles on supply chain:
US regulators create national database to track truckers’ drug, alcohol testing records: 4 things to know
Global prescription drug spending to hit $1.5 trillion by 2021: 6 findings
How drug prices spurred a shouting match between 2 pharma CEOs
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.